ClinicalTrials.gg
CompletedNCT01234779Updated Nov 2, 2016

A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia

A Phase 2 interventional study of bitopertin [RO4917838] and bitopertin [RO4917838] in Schizophrenia, sponsored by Hoffmann-La Roche. Completed at 46 sites in 5 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-11-02.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
301
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Schizophrenia by Hoffmann-La Roche — none open to participants now, none under way, none of them phase 3. Schizophrenia · Hoffmann-La Roche.

Enrollment
8th of 16
301 · median 294
Started
2011
with 2 others
Phase 2
5 of 19
none open now
Registered
9th of 19
by date

Among the 19 studies in Schizophrenia by Hoffmann-La Roche, this one is the 8th largest by enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2011, is one of 5 in phase 2, and was the 9th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 19 studies in Schizophrenia by Hoffmann-La Roche is open now. The open studies under Schizophrenia, anywhere →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Schizophrenia by Hoffmann-La Roche as a file.
02

Study summary

This randomized, double-blind, placebo- and active-controlled, parallel group study will evaluate the safety and efficacy of RO4917838 (bitopertin) in patients with acute exacerbation of schizophrenia. Patients will be randomized to receive either RO4917838 10 mg or RO4917838 30 mg or olanzapine 15 mg or placebo orally daily for 4 weeks as inpatients, with a 4-week follow-up period.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, 18-65 years of age
  • Diagnosis of schizophrenia ( DSM IV-TR)
  • Acute exacerbation which began within the prior 8 weeks
  • Female patients must be surgically sterile or , or agree to use effective for the duration of the study

Exclusion criteria

Exclusion Criteria:

  • Current psychiatric diagnosis other than schizophrenia
  • Alcohol or substance dependence within 3 months or abuse within 1 month (except for nicotine)
  • Electro-convulsive therapy (ECT) within the prior 6 months
  • Previous treatment with RO4917838 or another GLYT inhibitor
  • Current treatment with olanzapine, or previous treatment with intolerability or lack of response
  • Treatment with long-acting injectable antipsychotic within 2 dosing intervals
  • Treatment with > 2 antipsychotics within 3 months
  • History of neuroleptic malignant syndrome
  • Have treatment-resistant schizophrenia as judged by treating physician or have failed two trials according to criteria in protocol
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
301 participants (actual)

Study arms

  • Experimental
    A

    Drug: bitopertin [RO4917838]

  • Experimental
    B

    Drug: bitopertin [RO4917838]

  • Active comparator
    C

    Drug: olanzapine

  • Placebo comparator
    D

    Drug: placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Positive and Negative Syndrome Scale (PANSS) total score

    Time frame: from baseline to Day 28

  2. Safety: Incidence adverse events

    Time frame: 8 weeks

Secondary outcomes

  1. Clinical response, defined as at least 30% or 50% improvement from baseline PANSS total score

    Time frame: from baseline to Day 28

  2. Change in symptomatology as measured by the PANSS factor and subscale scores

    Time frame: from baseline to Day 28

  3. Global improvement as measured by the Clinical Global Impressions-Severity (CGI-S) scale

    Time frame: from baseline to Day 28

  4. Global improvement as measured by the Clinical Global Impressions-Change (CGI-C) rating scale

    Time frame: from baseline to Day 28

  5. Observable behavioural change as determined by the Nurses' Observation Scale For Inpatient Evaluation (NOSIE)

    Time frame: from baseline to Day 28

  6. Time to readiness for discharge from inpatient unit as assessed by the Readiness For Hospital Discharge Questionnaire (RDQ)

    Time frame: from baseline to Day 28

07

Study locations

46 sites
  • Little Rock, Arkansas 72201, United States
  • Cerritos, California 90703, United States
  • Oceanside, California 92056, United States
  • Pico Rivera, California 90660, United States
  • San Diego, California 92121, United States
  • Lauderhill, Florida 33021, United States
  • North Miami, Florida 33161, United States
  • Atlanta, Georgia 30308, United States
  • Lake Charles, Louisiana 70601, United States
  • Flowood, Mississippi 39232, United States
  • St. Louis, Missouri 63141, United States
  • Willingboro, New Jersey 08046, United States
  • Holliswood, New York 11423, United States
  • New York, New York 11004, United States
  • Cincinnati, Ohio 45219, United States
  • Philadelphia, Pennsylvania 19139, United States
  • Charlesston, South Carolina 29405, United States
  • Austin, Texas 78754, United States
  • Irving, Texas 75062, United States
  • Arad, 310022, Romania
  • Bucuresti, 010825, Romania
  • Bucuresti, 041902, Romania
  • Bucuresti, 041914, Romania
  • Foscani, 620165, Romania
  • Oradea, 410154, Romania
  • Targoviste, 130086, Romania
  • Gatchina, 188357, Russian Federation
  • Moscow, 117152, Russian Federation
  • Petrozavodsk, 186131, Russian Federation
  • St Petersburg, 190005, Russian Federation
  • St Petersburg, 193167, Russian Federation
  • St Petersburg, 194044, Russian Federation
  • St Petersburg, 197341, Russian Federation
  • St. Petersburg, 192019, Russian Federation
  • Talagi, 163530, Russian Federation
  • Bojnice, 972 01, Slovakia
  • Bratislava, 826 06, Slovakia
  • Liptovsky Mikulas, 3123, Slovakia
  • Michalovce, 071 01, Slovakia
  • Dnipropetrovsk, 49027, Ukraine
  • Donetsk, 83008, Ukraine
  • Kherson,Vil. Stepanivka, 73488, Ukraine
  • Kyiv, 02660, Ukraine
  • Kyiv, 04080, Ukraine
  • Poltava, 36006, Ukraine
  • Vinnytsya, 21005, Ukraine
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of Sep 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2010
First posted
Nov 4, 2010
Start
Feb 2011
Primary completionActual
Sep 2012
CompletionActual
Sep 2012
Results delay requested
Oct 7, 2013
Last update
Nov 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01234779
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 4, 2010
Start date
Feb 2011
Primary completion
Sep 2012
Completion
Sep 2012
Last update
Nov 2, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bitopertin

Start the discussion